An international panel of experts defined diagnostic criteria and appropriate utilization of multimodality imaging for evaluating patients with known or suspected cardiac amyloidosis.
This expert consensus document standardizes the diagnostic criteria and appropriate utilization of multimodality imaging for patients with known or suspected cardiac amyloidosis.
Cardiac amyloidosis is emerging as an underdiagnosed cause of heart failure and mortality. Growing literature suggests that a noninvasive diagnosis of cardiac amyloidosis is now feasible. However, the diagnostic criteria and utilization of imaging in cardiac amyloidosis are not standardized. In this paper, Part 2 of a series, a panel of international experts from multiple societies define the diagnostic criteria for cardiac amyloidosis and appropriate utilization of echocardiography, cardiovascular magnetic resonance imaging, and radionuclide imaging in the evaluation of patients with known or suspected cardiac amyloidosis.
Dorbala et al. (2019) conducted a review in Cardiac amyloidosis. Multimodality imaging (echocardiography, cardiovascular magnetic resonance, radionuclide imaging) was evaluated. An international panel of experts defined diagnostic criteria and appropriate utilization of multimodality imaging for evaluating patients with known or suspected cardiac amyloidosis.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: